Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00126945 | Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs | PHASE2 | COMPLETED | 125 | — | — | Aug 1, 2005 | Oct 1, 2005 | Sep 21, 2016 | 1 | Denmark |
| NCT00196963 | Evaluate 4 Different Formulations of Meningococcal Serogroups A, C, W-135, Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs | PHASE2 | COMPLETED | 125 | — | — | Mar 1, 2005 | Jul 1, 2005 | Sep 21, 2016 | 1 | Belgium |
| NCT00196950 | Study to Evaluate Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 18-25 Years | PHASE2 | COMPLETED | 50 | — | — | Sep 1, 2003 | Oct 1, 2003 | Sep 7, 2016 | 1 | Belgium |
| Name | Type | Description |
|---|---|---|
| Meningococcal Vaccine | BIOLOGICAL | - |
| Meningococcal (vaccine) | BIOLOGICAL | - |
Inclusion Criteria: * Healthy male or female between, and including, 15 and 19 years of age at the time of vaccination. * Subject with previously completed routine childhood vaccinations to the best of his/her knowledge or his/her parents'/guardians' knowledge. * Female subjects should be of non-ch...